title: [The clinical features of B cell lymphoblastic lymphoma and outcomes after BFM-90 regimen therapy].
abstract: OBJECTIVE
  To analyse the clinical features of patients with B cell lymphoblastic lymphoma(BCLL) and the outcomes after modified BFM-90 protocol therapy.
  
  
  METHODS
  The clinical features of 14 patients with BCLL were analysed, and compared with that of T cell lymphoblastic lymphoma in the same period. The efficacy and toxicity of modified BFM-90 protocol were analysed.
  
  
  RESULTS
  The 14 patients were aged 3 to 18 and diagnosed as BCLL by morphology and immunohistology. One case was in stage I , 2 stage III and 11 stage IV. Most common involved sites were lymph nodes (70% ), skin (50% ) and bone marrow (64% ). One patient received CHOP + HD-MTX, and 13 received modified BFM-90 protocol chemotherapy. Twelve patients (92.3%) achieved complete remission( CR) , 1 patient(7. 7% ) partial remission( PR). The median follow-up duration was 19. 5 months (2 to 44 months). At present 13 patients are alive except one PR patient who gave up treatment and died of disease. The major toxicity of the protocol was myelosuppression, but could be tolerated.
  
  
  CONCLUSIONS
  The most common involvement sites of BCLL were lymph nodes, skin and bone marrow. The effectiveness is improved as treated with modified BFM-90 protocol.
authors.affiliation: Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China.
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Sun
authors.forename: Zi-jun
authors.initials: ZJ
authors.lastname: Zhen
authors.forename: Yi
authors.initials: Y
authors.lastname: Xia
authors.forename: Qun-ying
authors.initials: QY
authors.lastname: Yang
authors.forename: Zhi-hui
authors.initials: ZH
authors.lastname: Wang
authors.forename: Jia-yu
authors.initials: JY
authors.lastname: Ling
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D015122:Mercaptopurine; D008727:Methotrexate